

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): August 9, 2017

**United-Guardian, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction of Incorporation)

**001-10526**  
(Commission File Number)

**11-1719724**  
(I.R.S. Employer Identification Number)

**230 Marcus Boulevard, Hauppauge, New York 11788**  
(Address of Principal Executive Offices) (Zip Code)

**(631) 273-0900**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 2.02. Results of Operations and Financial Condition.**

On August 9, 2017, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

Exhibit 99.1. Press release dated August 9, 2017

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**United-Guardian, Inc.**

Date: August 9, 2017

By: /s/ Ken Globus  
Ken Globus  
President

### United-Guardian Reports Strong 2nd Quarter and 6-Month Results

HAUPPAUGE, N.Y., Aug. 09, 2017 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported today that sales for the second quarter of 2017 increased by 76% compared with the same period last year, growing from \$2,215,952 to \$3,891,656. As a result, net income for the quarter increased 172% from \$405,381 (\$0.09 per share) to \$1,104,149 (\$0.24 per share). For the six-month period ended June 30, 2017, sales increased by 49% and net income increased by 87%, resulting in earnings per share of \$0.38 compared with \$0.20 for the comparable 6-month period in 2016.

Ken Globus, President of United-Guardian, stated, "As a result of the resumption of shipments of one of our personal care products to China, as well as an increase in sales of our new single-dose form of Renacidin<sup>®</sup> Irrigation, our most important pharmaceutical product, we were able to significantly increase our sales and earnings for the second quarter of this year compared with the same period last year. Overall, sales of our personal care products increased by 131% compared with last year's second quarter, and by 82% when compared with the first six months of 2016. In addition, pharmaceutical sales increased by 40% for the second quarter of 2017 compared with last year's second quarter, and by 46% for the first six months of 2017 compared with the same period last year. We remain optimistic that we will continue to see strong sales of both of these product lines as the year progresses."

United-Guardian is a manufacturer of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products.

NOTE: This press release contains both historical and "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company's expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the "safe harbor" provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company's business please refer to the company's reports and filings with the Securities and Exchange Commission.

#### RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2017 and 2016

	THREE MONTHS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,	
	<u>2017</u>	<u>2016</u>	<u>2017</u>	<u>2016</u>
Sales:				
Gross sales	\$ 3,891,656	\$ 2,215,952	\$ 6,764,379	\$ 4,546,529
Sales rebates and allowances	(116,905)	(76,787)	(203,240)	(144,788)
<b>Net Sales</b>	<u>3,774,751</u>	<u>2,139,165</u>	<u>6,561,139</u>	<u>4,401,741</u>
Costs and expenses:				
Cost of sales	1,667,113	1,007,666	2,931,209	1,905,391
Operating expenses	418,605	465,329	882,085	932,885
Research and development	158,275	157,895	348,004	335,461
<b>Total costs and expenses</b>	<u>2,243,993</u>	<u>1,630,890</u>	<u>4,161,298</u>	<u>3,173,737</u>
<b>Income from operations</b>	<u>1,530,758</u>	<u>508,275</u>	<u>2,399,841</u>	<u>1,228,004</u>
Investment income	72,796	82,906	125,668	126,218
<b>Income before provision for</b>	<u>1,603,554</u>	<u>591,181</u>	<u>2,525,509</u>	<u>1,354,222</u>

**income taxes**

Provision for income taxes	<u>499,405</u>	<u>185,800</u>	<u>786,925</u>	<u>423,750</u>
<b>Net Income</b>	\$ <u><u>1,104,149</u></u>	\$ <u><u>405,381</u></u>	\$ <u><u>1,738,584</u></u>	\$ <u><u>930,472</u></u>

**Earnings per common share**

<b>(Basic and Diluted)</b>	\$ <u><u>0.24</u></u>	\$ <u><u>.09</u></u>	\$ <u><u>0.38</u></u>	\$ <u><u>0.20</u></u>
----------------------------	-----------------------	----------------------	-----------------------	-----------------------

Additional financial information can be found at the company's web site at [www.u-g.com](http://www.u-g.com).

Contact:

Robert S. Rubinger

Public Relations

(631) 273-0900